连续输注油酸的急性呼吸衰竭猪模型
2024年3月8日
2.1K 次观看
将油酸连续注入麻醉成年猪的肺动脉会诱发急性呼吸衰竭，从而在急性呼吸失代偿期间进行受控实验。
我们团队的转化研究是血管波形，特别是低频静脉波形，在各种容量和呼吸状态下如何变化。我们正在努力更好地了解静脉波形以及呼吸系统如何影响它们。我们的研究表明，分析呼吸频率和脉搏率的基频以计算 RIVA-RI 比率有助于定量监测与 PaO2 相关的患者氧疗需求。
这可能会导致一种无创工具，用于对急性呼吸功能不全、哮喘恶化、慢性阻塞性肺病、肺气肿或特发性肺纤维化患者进行分类。鉴于我们研究的新颖性，在人类身上获得这些静脉波形是一个巨大的挑战，而且在很多情况下并不实用。这就是为什么像这样的猪模型对我们的工作和我们希望实现的目标如此重要。
我们研究的重要发现是，来自静脉侧的波形（一个传统上被忽视的领域）包含大量信息。我们发现这些静脉信号对容量状态和呼吸状况的变化都非常敏感。这一发现为增强人类无创呼吸监测带来了希望。
概述
本研究探讨了持续注入油酸到麻醉成年猪的肺动脉导致急性呼吸衰竭的影响。这一模型允许在急性呼吸衰竭期间进行受控实验。
关键研究组成部分
科学领域
- 呼吸生理学
- 转化研究
- 血管波形分析
背景
- 了解不同呼吸状态下的静脉波形至关重要。
- 分析呼吸和脉率可以为氧疗需求提供信息。
- 猪模型对于研究类似人类的呼吸状况至关重要。
- 静脉波形包含重要但常被忽视的信息。
研究目的
- 探索呼吸系统如何影响静脉波形。
- 开发一种用于监测急性呼吸衰竭的非侵入性工具。
- 将静脉波形分析与患者氧疗需求相关联。
所用方法
- 持续注入油酸到肺动脉。
- 监测呼吸和脉率。
- 分析RIVA-RI比例以进行患者分类。
- 利用猪模型进行实验验证。
主要结果
- 油酸注入成功诱导了急性呼吸衰竭。
- 观察到静脉波形的显著变化。
- 该研究强调了静脉波形分析的重要性。
- 研究结果支持非侵入性监测工具的潜力。
结论
- 静脉波形为呼吸状况提供了宝贵的洞察。
- 猪模型对于研究人类呼吸问题是有效的。
- 进一步研究可能导致改进的患者管理策略。
常见问题
静脉波形的意义是什么？
静脉波形可以揭示有关呼吸状态和患者氧气需求的重要信息。
为什么在这项研究中使用猪模型？
猪模型能够很好地模拟人类生理，使其成为研究呼吸状况的理想选择。
油酸注入如何影响呼吸？
注入油酸可以诱发急性呼吸衰竭，从而允许进行受控实验。
什么是RIVA-RI比例？
RIVA-RI比例是一种用于监测患者氧疗需求的计算指标。
这项研究的潜在应用是什么？
这项研究可能导致用于对呼吸衰竭患者进行分类的非侵入性工具。
在人类中获取静脉波形存在哪些挑战？
在人类中获取静脉波形通常是不切实际的，并且存在重大挑战。
Executive Industry Relevance
Robust preclinical models of acute respiratory failure are essential for translational research targeting respiratory insufficiency and related vascular dynamics. The continuous oleic acid infusion porcine model enables controlled induction and monitoring of acute respiratory decompensation, supporting mechanistic de-risking and predictive confidence in respiratory biomarker development. This model underpins early-stage pipeline decisions for non-invasive monitoring tool validation and respiratory therapeutic hypothesis testing.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of respiratory pathophysiology and vascular waveform dynamics in a controlled, disease-relevant system.
- Supports functional validation of respiratory and hemodynamic biomarkers for acute decompensation.
- Facilitates mechanistic de-risking by correlating venous waveform changes with respiratory status and oxygenation metrics.
Screening & Assay Development
- Provides a validated in vivo platform for quantitative measurement of respiratory and hemodynamic parameters.
- Enables reproducible assessment of candidate biomarkers and monitoring technologies under acute respiratory stress.
- Supports standardization of physiological readouts for downstream translational workflows.
Translational & Preclinical Research
- Aligns with disease-relevant endpoints for acute respiratory failure and vascular response.
- Bridges discovery-stage biomarker findings to preclinical validation in a human-analogous model.
- Informs risk-adjusted advancement of non-invasive monitoring strategies for respiratory insufficiency.
Pipeline & Workflow Integration
This porcine model integrates into the discovery-to-preclinical continuum for respiratory and vascular biomarker research, supporting both early mechanistic studies and translational validation.
- Discovery Biology: Enables hypothesis testing on the interplay between respiratory failure and venous waveform alterations.
- Screening: Provides quantitative, reproducible physiological outputs for candidate biomarker evaluation.
- Analytics: Delivers continuous measurements of oxygenation, hemodynamics, and waveform metrics for comparative analysis.
- Translational Research: Offers a platform for aligning preclinical findings with clinical endpoints in acute respiratory distress.
- Enterprise Reuse: Establishes a reusable, scalable model for respiratory and vascular research across multiple programs.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in respiratory biomarker and monitoring tool development.
- Operational Value: Standardizes acute respiratory failure induction and monitoring for reproducibility.
- Strategic Value: Supports informed go/no-go decisions for translational respiratory research investments.
- Portfolio Impact: Enables risk-adjusted prioritization of respiratory and vascular monitoring technologies.
Implementation Considerations
- Requires expertise in large animal anesthesia, vascular access, and hemodynamic monitoring.
- Demands access to advanced physiological monitoring and waveform analysis instrumentation.
- Necessitates cross-team standardization of data collection and analysis protocols.
- Adaptation to other large animal models may require protocol optimization.
- Model limitations include species-specific responses and resource-intensive setup.
Biopharma FAQs
Why does null hypothesis testing matter for venous waveform target validation?
Null hypothesis testing in this model allows teams to rigorously determine whether observed changes in venous waveforms are statistically linked to induced respiratory failure, supporting robust target validation for respiratory biomarkers.
How does independent variable isolation fit the oleic acid infusion pipeline?
By controlling the oleic acid infusion rate and monitoring specific physiological parameters, the model isolates the impact of acute respiratory distress on vascular waveforms, clarifying mechanistic relationships for discovery-stage research.
What do quantitative dependent variable measurements enable in this porcine model?
Quantitative tracking of oxygenation, hemodynamics, and waveform metrics enables precise comparison of respiratory states and supports the evaluation of candidate monitoring tools or biomarkers under controlled conditions.
Why are replication requirements critical for cross-functional respiratory research?
Replication ensures that observed physiological and waveform changes are reproducible across animals and experimental runs, facilitating cross-team data integration and increasing confidence in translational findings.
What statistical analysis capabilities are required before implementing waveform-based monitoring tools?
Robust statistical analysis is needed to correlate waveform changes with respiratory endpoints, establish significance thresholds, and validate predictive performance prior to advancing monitoring tools toward clinical translation.
